The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study
| العنوان: | The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study |
|---|---|
| المؤلفون: | Lars Bastholt, Ivan Marquez Rodas, Jochen Utikal, Pier Francesco Ferrucci, Harriet Tuson, Luc Thomas, Miranda Payne, Pascal Wolter, Caroline Robert, J McKendrick, Johan Hansson, Paolo A. Ascierto, Amber Kudlac |
| المصدر: | Melanoma Research Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Ascierto, P A, Bastholt, L, Ferrucci, P F, Hansson, J, Márquez Rodas, I, Payne, M, Robert, C, Thomas, L, Utikal, J S, Wolter, P, Kudlac, A, Tuson, H & McKendrick, J 2018, ' The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma : Results from a European expert panel study ', Melanoma Research, vol. 28, no. 4, pp. 333-340 . https://doi.org/10.1097/CMR.0000000000000455Test |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Disease specific, Male, Proto-Oncogene Proteins B-raf, advanced melanoma, Cancer Research, medicine.medical_specialty, Skin Neoplasms, BRAF/MEK inhibitors, medicine.medical_treatment, Delphi method, Patient characteristics, Dermatology, Targeted therapy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Surveys and Questionnaires, medicine, Humans, Intensive care medicine, Melanoma, Advanced melanoma, business.industry, factors, selecting therapy, medicine.disease, ORIGINAL ARTICLES: Clinical research, expert opinion, First line treatment, Europe, Oncology, first-line treatment decision, 030220 oncology & carcinogenesis, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, Treatment decision making, immunotherapy, business, checkpoint inhibitors |
| الوصف: | Supplemental Digital Content is available in the text. Treatment decisions for advanced melanoma are increasingly complex and guidelines provide limited advice on how to choose between immunotherapy and targeted therapy for first-line treatment. A Delphi study was carried out to understand which patient characteristics and disease-related factors inform clinicians’ choices of first-line treatment for BRAF-mutated melanoma. Twelve European melanoma specialists experienced in using immunotherapies and targeted agents participated in a double-blind two-phase Delphi study. In phase 1, participants completed a questionnaire developed after reviewing patient characteristics and disease-related factors reported in trials, clinical guidelines, and health technology assessments. Phase 2 was an expert panel meeting to explore outstanding issues from phase 1 and seek consensus, defined as 80% agreement. Twenty patient-related and disease-related characteristics were considered. There was consensus that tumor burden (83% of clinicians) and disease tempo (83%) are very or extremely important factors when selecting first-line treatment. Several components were deemed important when assessing tumor burden: brain metastases (82% of clinicians) and location of metastases (89%). There was consensus that disease tempo can be quantified in clinical practice, but not on a formal classification applicable to all patients. Lactate dehydrogenase level is a component of both tumor burden and disease tempo; all clinicians considered lactate dehydrogenase important when choosing first-line treatment. The majority (92%) did not routinely test programmed death ligand-1 status in patients with melanoma. Clinicians agreed that choosing a first-line treatment for advanced melanoma is a complex, multifactorial process and that clinical judgment remains the most important element of decision-making until research can provide clinicians with better scientific parameters and tools for first-line decision-making. |
| وصف الملف: | application/pdf |
| تدمد: | 1473-5636 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee4e9e62e780a228a3f3cccf6e9e120Test https://pubmed.ncbi.nlm.nih.gov/29750751Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9ee4e9e62e780a228a3f3cccf6e9e120 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14735636 |
|---|